Clinical trials: Nutrition Disorder
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with…
- Trial name
- NCT04483947
- Testing
- AZD2693
- Where
- 16 sites in United States
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Metabolism and Nutrition Disorder, Obesity
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight
This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability, Pharmacokinetics (the exposure of the trial drug in the body) and Pharmacodynamics (the effect of the…
- Trial name
- NCT02958085
- Testing
- NNC0174-0833
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Novo Nordisk A/S
Hyperglycemia, Diabetics
Clinical Evaluation of a Specific Enteral Diet for Diabetics
The hypothesis of the proposed trials is that the regular intake of a specific diet designed for enteral nutrition of type 2 diabetic patients results into a better nutritional status.
- Conditions
- Hyperglycemia, Diabetics, Metabolic Syndrome
- Trial name
- NCT01247714
- Testing
- T-Diet plus Standard, T-Diet plus Diabet NP, Glucerna
- Where
- Spain
- Volunteers
- 43 people
- Sponsor
- Vegenat, S.A.
Obesity
Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects
The purpose of this open-label extension study is to evaluate the safety and efficacy of velneperit (S-2367) in obese subjects.
- Trial name
- OLE (NCT00788528)
- Testing
- S-2367 (velneperit)
- Where
- 73 sites in United States
- Volunteers
- 766 people, healthy volunteers welcome
- Sponsor
- Shionogi
Obstructive Sleep Apnea
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are…
- Trial name
- MARITIME-OSA-2 (NCT07226765)
- Testing
- Maridebart cafraglutide
- Where
- 57 sites in United States, Australia and 9 more
- Volunteers
- 250 people
- Sponsor
- Amgen
Obesity, Hepatic Insufficiency
Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
CP-945,598 is eliminated following extensive metabolism. Decrease hepatic function can affect its elimination from the body via metabolism.
- Trial name
- NCT00645021
- Testing
- CP-945,598
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overweight, Obesity
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
The purpose of this study is to learn more about how tirzepatide affects stomach emptying in overweight/very overweight participants. Participants include those without diabetes and those with type 2 diabetes.
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04407234
- Testing
- Tirzepatide, Acetaminophen
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Weight Maintenance, Overweight
Litramine in Weight Maintenance
The effect of Litramine on weight loss has previously been studied during a 12-week intervention period with promising results. The present study looks into the effect of weight maintenance using Litramine following initial…
- Conditions
- Weight Maintenance, Overweight, Obese
- Trial name
- NCT01505387
- Testing
- Litramine
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity
A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes
The purpose of this study is to test the safety and effectiveness of JNJ-28431754 in promoting weight loss in patients who are overweight or obese and who do not have diabetes.
- Trial name
- NCT00650806
- Testing
- Canagliflozin (JNJ-28431754)
- Where
- 36 sites in United States, Puerto Rico
- Volunteers
- 376 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Infant Nutrition Disorders, Weight Loss
Feasibility and Validation of a Smart Changing Pad for Home Infant Weight Monitoring After Hospital Discharge
This pilot study evaluates the feasibility, usability, and clinical utility of the Woddle Smart Changing Pad and companion mobile application for infant monitoring following hospital or NICU discharge.
- Conditions
- Infant Nutrition Disorders, Weight Loss, Postnatal Care, Premature Birth
- Trial name
- NCT07718516
- Testing
- Woddle Smart Changing Pad
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Stan Kachnowski
Obesity / Overweight, Obesity (BMI Equal to or >30)
A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS.
This study is designed as a single-blind, placebo-controlled, randomized, parallel-group trial. Subjects will be randomized in a 2:1 ratio to receive either NKS-3 or matching placebo, with a total planned enrollment of 31…
- Trial name
- SERENITY-1 (NCT07882654)
- Testing
- Investigational product is a modified linoleic acid, named NKS-3. This non-caloric agent, synthetized from linoleic acid, is a fat taste receptors agonist, targeting CD36 with also an impact on GPR120
- Where
- Tunisia
- Volunteers
- 31 people
- Sponsor
- EktaH
Type 2 Diabetes Mellitus (T2DM), Overweight or Obese
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function
The purpose of this study is to assess how fast BGM0504 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
- Trial name
- NCT06929156
- Testing
- BGM0504
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Dyslipidemia, Obesity &Amp; Overweight
Improvement and Safety of Nutrilite Protein MetX Pro on Weight Management in Overweight Individuals With Dyslipidemia
The goal of this randomized, double-blind, placebo-controlled, single center study is to evaluate the impact of Nutrilite Protein MetX Pro (the study product, a high-protein compound beverages supplemented with multiple plant…
- Trial name
- NCT07094022
- Testing
- Nutrilite Protein MetX Pro
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Amway (China) R&D Center
Obesity
To Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects
To Evaluate the safety, tolerability and pharmacokinetic property after KD101 multiple oral dosing in the fed state in obese or overweight subjects.
- Trial name
- NCT02462031
- Testing
- KD101
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Obesity
A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide
This is a study of tirzepatide in participants with obesity. The main purpose is to learn more about how tirzepatide affects the number of calories participants burn and the amount of food they eat.
- Trial name
- NCT04081337
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Eli Lilly and Company
Congestive Heart Failure
Assess Measurements of Wireless Cardiac Output Device
Heart failure is a common cardiovascular problem which is increasing in both prevalence and incidence and associated with substantial morbidity and mortality.
- Trial name
- Remote-CO-1 (NCT02252757)
- Testing
- CoVa
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Aventyn, Inc.
Obesity, Type 2 Diabetes Mellitus
XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults
XW004 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
- Trial name
- NCT05184322
- Testing
- T2026, Oral ecnoglutide tablet
- Where
- Australia
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Prader-Willi Syndrome
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome
To evaluate the effectiveness of rhGH (Recombinant human growth hormone) injection for improving motor development in patients with PWS.
- Trial name
- NCT03554031
- Testing
- Recombinant Human Growth Hormone (rhGH) Injection
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Obesity
Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108
The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108.
- Trial name
- NCT07153172
- Testing
- INV-347
- Where
- Canada
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo).
- Trial name
- OASIS 5 (NCT07770841)
- Testing
- Semaglutide
- Where
- 62 sites in United States, Belgium and 8 more
- Volunteers
- 450 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.